TY - JOUR
T1 - Vitamin K antagonist reversal strategies
T2 - Systematic review and network meta-analysis from the AABB
AU - Pagano, Monica B.
AU - Foroutan, Farid
AU - Goel, Ruchika
AU - Allen, Elizabeth S.
AU - Cushing, Melissa M.
AU - Garcia, David A.
AU - Hopkins, Courtney K.
AU - Klein, Kimberly
AU - Raval, Jay S.
AU - Cohn, Claudia S.
N1 - Publisher Copyright:
© 2022 AABB.
PY - 2022/8
Y1 - 2022/8
N2 - Background: Anticoagulation requires urgent reversal in cases of life-threatening bleeding or invasive procedures. Study Design and Methods: Network meta-analysis for comparing the safety and efficacy of warfarin reversal strategies including plasma and prothrombin complex concentrates (PCCs). Results: Seven studies including 594 subjects using reversal agents plasma, 3-factor-PCC (Uman Complex and Konyne), and 4-factor-PCC (Beriplex/KCentra, Octaplex, and Cofact) met inclusion criteria. Compared with plasma, patients receiving Cofact probably have a higher rate of international normalized ratio (INR) correction (risk difference [RD] 499 more per 1000 patients, 95% confidence interval [CI], 176–761, low certainty[LC]); higher reversal of bleeding (323 more per 1000 patients, 11–344 more, LC); and fewer transfusion requirements (0.96 fewer units, 1.65–0.27 fewer, LC). Patients receiving Beriplex/KCentra probably have a higher rate of INR correction (476 more per 1000 patients, 332–609 more, LC); higher reversal of bleeding (127 more per 1000 patients, 43 fewer to 236 more); and similar transfusion requirements (0.01 fewer units, 0.31 fewer to 0.28 more, high/moderate certainty). Patients receiving Octaplex probably have a higher rate of INR correction (RD 579 more per 1000 patients, 189–825 more, LC). Conclusions: PCCs probably provide an advantage in INR reversal compared to plasma. There was no added risk of adverse events with PCCs.
AB - Background: Anticoagulation requires urgent reversal in cases of life-threatening bleeding or invasive procedures. Study Design and Methods: Network meta-analysis for comparing the safety and efficacy of warfarin reversal strategies including plasma and prothrombin complex concentrates (PCCs). Results: Seven studies including 594 subjects using reversal agents plasma, 3-factor-PCC (Uman Complex and Konyne), and 4-factor-PCC (Beriplex/KCentra, Octaplex, and Cofact) met inclusion criteria. Compared with plasma, patients receiving Cofact probably have a higher rate of international normalized ratio (INR) correction (risk difference [RD] 499 more per 1000 patients, 95% confidence interval [CI], 176–761, low certainty[LC]); higher reversal of bleeding (323 more per 1000 patients, 11–344 more, LC); and fewer transfusion requirements (0.96 fewer units, 1.65–0.27 fewer, LC). Patients receiving Beriplex/KCentra probably have a higher rate of INR correction (476 more per 1000 patients, 332–609 more, LC); higher reversal of bleeding (127 more per 1000 patients, 43 fewer to 236 more); and similar transfusion requirements (0.01 fewer units, 0.31 fewer to 0.28 more, high/moderate certainty). Patients receiving Octaplex probably have a higher rate of INR correction (RD 579 more per 1000 patients, 189–825 more, LC). Conclusions: PCCs probably provide an advantage in INR reversal compared to plasma. There was no added risk of adverse events with PCCs.
KW - anticoagulation
KW - prothrombin complex concentrate
KW - warfarin
UR - http://www.scopus.com/inward/record.url?scp=85134057032&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85134057032&partnerID=8YFLogxK
U2 - 10.1111/trf.17010
DO - 10.1111/trf.17010
M3 - Article
C2 - 35834523
AN - SCOPUS:85134057032
SN - 0041-1132
VL - 62
SP - 1652
EP - 1661
JO - Transfusion
JF - Transfusion
IS - 8
ER -